Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Nortran Pharmaceutical -NRT.V -- Ignore unavailable to you. Want to Upgrade?

To: Corbin who wrote (972)	10/19/1998 4:45:00 PM
From: RBMac	Read Replies (1) \| Respond to of 1185

Reaches Agreement with Inveresk Research NORTRAN PHARMACEUTICALS INC ("NRT-V;NTRDF-L") - Reaches Agreement with Inveresk Research Robert Rieder, Chief Executive Officer of Nortran Pharmaceuticals Inc. (the "Company"), announced that it has reached an agreement with Inveresk Research, a contract research organization based in Scotland, U.K., to conduct pre-clinical toxicology studies on the Company's compound for the treatment of intractable cough. The Company recently received 5 kilograms of the GMP synthesized compound through its agreement with Abbott Laboratories, and is preparing to commence the final pre-clinical work with Inveresk in preparation for filing an upcoming IND and conducting phase I clinical trials. These studies are expected to last for approximately 6 months and will be conducted at Inveresk's facilities in the U.K. Inveresk Research is a fully Good Laboratory Practices, Good Manufacturing Practices, and Good Clinical Practices compliant facility with over 30 years of experience serving the pharmaceutical industry. Nortran's cough compound is initially aimed at markets for acute, intractable cough, such as is experienced by individuals who suffer from asthma, chronic obstructive pulmonary disorder, or lung cancer. Testing to date has indicated that the Company's cough compound eliminates cough very effectively, and since it has previously undergone safety trials in humans for another indication, the Company is confident of the drug's safety profile. Phase I clinical trials are anticipated to begin by mid 1999. Nortran Pharmaceuticals is a drug discovery company focusing on pathology targeted small molecules. The Company previously announced a partnership with F. Hoffman La-Roche covering part of its antiarrhythmic development program in the area of a trial fibrillation. Nortran's current drugs in development target life-threatening arrhythmias of the heart, pain management, sexual dysfunction and acute cough. Warning: The company relies on litigation protection for "forward-looking" statements. TEL: (604) 222-5577 Nortran Pharmaceuticals Inc. FAX: (604) 222-6617 James King, Corporate Communications Email: admin@nortran.com Internet: Website: nortran.com ______________________________________ (c) Corporate Dissemination Services Inc. All rights reserved. Tel:(604) 689-1101 Fax:(604) 689-1106 RapidFAX (tm) - To get the NEWS as it happens, call (604) 689-3041.